Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476).

James, Nicholas D.; Sydes, Matthew R.; Mason, Malcolm David; Clarke, Noel W.; Dearnaley, David P.; Spears, Melissa; Millman, Robin; Parker, Chris; Ritchie, A. W. S.; Russell, John M.; Staffurth, John; Jones, Robert J.; Tolan, Shaun; Wagstaff, John; Protheroe, Andrew; Srinivasan, Rajaguru; Birtle, Alison; Cathomas, Richard; Parmar, Mahesh; Investigators, Stampede

doi:10.1200/jco.2015.33.15_suppl.5001

Cited by 105 publications

(82 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, adding zoledronic acid to standard therapy did not affect survival, and adding the combination of zoledronic acid and docetaxel was not more effective than adding just docetaxel. These findings were presented on 13 May at a presscast in advance of the ASCO 2015 [39]. These and other upcoming trials will begin to define the role of more effective systemic therapy in hormone-sensitive prostate cancer.…”

Section: Role Of Chemotherapy In Hormone-sensitive Diseasementioning

confidence: 80%

New advances in genitourinary cancer: evidence gathered in 2014

Suárez

Puente

Gallardo³

et al. 2015

Cancer Metastasis Rev

View full text Add to dashboard Cite

This review provides updated information published in 2014 regarding advances and major achievements in genitourinary cancer. Sections include the best in prostate cancer, renal cancer, bladder cancer, and germ cell tumors. In the field of prostate cancer, data related to treatment approach of hormone-sensitive disease, castrate-resistant prostate cancer, mechanisms of resistance, new drugs, and molecular research are presented. In relation to renal cancer, relevant aspects in the treatment of advanced renal cell carcinoma, immunotherapy, and molecular research, including angiogenesis and von Hippel-Lindau gene, molecular biology of non-clear cell histologies, and epigenetics of clear renal cell cancer are described. New strategies in the management of muscle-invasive localized bladder cancer and metastatic disease are reported as well as salient findings of biomolecular research in urothelial cancer. Some approaches intended to improve outcomes in poor prognosis patients with metastatic germ cell cancer are also reported. Results of clinical trials in these areas are discussed.

show abstract

Section: Role Of Chemotherapy In Hormone-sensitive Diseasementioning

confidence: 80%

New advances in genitourinary cancer: evidence gathered in 2014

Suárez

Puente

Gallardo³

et al. 2015

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…The STAMPEDE trial uses a novel, multi-arm, multi-stage design, enrolling men with locally advanced or metastatic prostate cancer being started on long-term ADT. The addition of docetaxel to long-term ADT in this heterogeneous cohort improved median survival by 10 months (77 vs. 67 months) and resulted in a statistically significant improvement in survival (hazard ratio 0.76 [95 % CI 0.63-0.91; p = 0.003]) [52]. Interestingly, a French multicenter trial also evaluating early docetaxel and ADT for hormone-naïve metastatic prostate cancer, GETUG-15, failed to demonstrate a survival advantage compared to ADT alone [53].…”

Section: Neoadjuvant Chemotherapy and Chemohormonal Therapymentioning

confidence: 91%

Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy

Pietzak

Eastham

2016

Curr Urol Rep

View full text Add to dashboard Cite

Multimodal strategies combining local and systemic therapy offer the greatest chance of cure for many with men with high-risk prostate cancer who may harbor occult metastatic disease. However, no systemic therapy combined with radical prostatectomy has proven beneficial. This was in part due to a lack of effective systemic agents; however, there have been several advancements in the metastatic and castrate-resistant prostate cancer that might prove beneficial if given earlier in the natural history of the disease. For example, novel hormonal agents have recently been approved for castration-resistant prostate cancer with some early phase II neoadjuvant showing promise. Additionally, combination therapy with docetaxel-based chemohormonal has demonstrated a profound survival benefit in metastatic hormone-naïve patients and might have a role in eliminating pre-existing ADT-resistant tumor cells in the neoadjuvant setting. The Cancer and Leukemia Group B (CALGB)/Alliance 90203 trial has finished accrual and should answer the question as to whether neoadjuvant docetaxel-based chemohormonal therapy provides an advantage over prostatectomy alone. There are also several promising targeted agents and immunotherapies under investigation in phase I/II trials with the potential to provide benefit in the neoadjuvant setting.

show abstract

“…Preliminary data in the Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) trial observed a median overall survival benefit of docetaxel 1 ADT of 10 months (HR, 0.76; 95% CI, 0.63-0.91; P 5 .003) versus standard of care. 80 Of note, the median age of patients in this study is 65 years, and among those randomized to the docetaxel 1 ADT arm, 50% experienced a grade 3 to 5 toxicity versus 31% patients receiving standard of care (no P value available). 80 Certainly, more work is needed in this area to clarify the benefit of adding docetaxel to ADT for high-risk locally advanced PCa and mCRPC.…”

Section: Chemotherapymentioning

confidence: 98%

“…80 Of note, the median age of patients in this study is 65 years, and among those randomized to the docetaxel 1 ADT arm, 50% experienced a grade 3 to 5 toxicity versus 31% patients receiving standard of care (no P value available). 80 Certainly, more work is needed in this area to clarify the benefit of adding docetaxel to ADT for high-risk locally advanced PCa and mCRPC. In addition, it is important to consider the generalizability of such results to older adults, especially considering the high incidence of grade 3 to 5 toxicity reported among a relatively younger, fitter study population.…”

Section: Chemotherapymentioning

confidence: 98%